Werewolf Therapeutics

Novel IL-2 Derivative Shows Complete Remission in Advanced Skin Cancer Patient After One Year

4 days ago

• A 73-year-old patient with advanced cutaneous squamous cell carcinoma has remained cancer-free for over a year following treatment with WTX-124, a novel conditionally activated IL-2 pro-drug, in a clinical trial at HonorHealth Research Institute. • The investigational drug is engineered to remain inactive until it reaches the tumor microenvironment, potentially delivering the benefits of IL-2 therapy with significantly reduced toxicity compared to conventional treatments. • This breakthrough offers new hope for the nearly 40,000 U.S. patients annually who develop advanced cutaneous squamous cell carcinoma, particularly those who have failed standard treatments including checkpoint inhibitor therapy.

Jazz Pharmaceuticals Acquires Global Rights to Zanidatamab in $1.76 Billion Deal with Zymeworks

3 months ago

• Jazz Pharmaceuticals secures exclusive development and commercialization rights to zanidatamab, a novel HER2-targeted bispecific antibody, in a deal potentially worth $1.76 billion plus royalties. • Zanidatamab shows promising anti-tumor activity in HER2-expressing cancers and has received FDA Breakthrough Therapy designation for biliary tract cancer treatment. • The agreement includes a $50 million upfront payment, with potential additional payments of $525 million for regulatory milestones and $862.5 million for commercial achievements.

Werewolf Therapeutics Announces 2025 Milestones for IL-2 and IL-12 INDUKINE Programs

4 months ago

• Werewolf Therapeutics anticipates sharing preliminary monotherapy data for WTX-124 in H1 2025, potentially guiding regulatory engagement for accelerated approval. • A Phase 1/2 clinical trial of WTX-330, an IL-12 INDUKINE molecule, is expected to begin in Q1 2025, targeting immunotherapy-resistant cancers. • Interim data from combination expansion arms of WTX-124 with pembrolizumab are expected in Q4 2025, further evaluating its efficacy in solid tumors. • Werewolf's cash position is expected to fund operations through at least the second quarter of 2026, supporting ongoing clinical development.

Sanofi Halts Phase 2 Trials of IL-2 Cancer Drug SAR444245 After Disappointing Efficacy

a year ago

• Sanofi is halting Phase 2 trials for its IL-2 cancer drug candidate, SAR444245, due to lower-than-projected efficacy in mid-stage clinical data. • The company will restart the program with Phase 1/2 trials, adjusting the dosing schedule to improve the drug's target profile. • This decision results in a nearly €1.6 billion impairment charge, attributed to delays in launch timelines for key indications. • Sanofi acquired SAR444245 through its $2.5 billion acquisition of Synthorx in 2019, aiming for a safer, more precise IL-2 therapy.